OncLive eNewsletter Signup
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung…
In a recent study, researchers at Huntsman Cancer Institute found a trend in families with male infertility: an increased risk of certain cancers.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Discuss efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML…